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Introduction 16
Alzheimer's disease (AD) is a debilitating neurological condition that is characterized by a 17 progressive deterioration in cognitive function and concomitant functional decline. While the 18 classical neuropathological hallmarks of AD are the deposition of neuritic plaques and 19 neurofibrillary tangles, increasing evidence has highlighted the role of neuroinflammation and 20 microglial innate immune response in AD pathogenesis [1] . 21
22
Chronic systemic inflammation may also be associated with an increased risk of developing 23 dementia [2], with higher levels of serum proinflammatory cytokines being reported in patients 24 with AD [3] . Chronic systemic inflammation is characterized by the production of the 25 proinflammatory cytokine tumor necrosis factor α (TNF-α) from macrophages. TNF-α is involved 26 in the pathogenesis of chronic autoimmune disorders such as rheumatoid arthritis (RA), but also 27 plays a role in activation of the central innate immune response, including in microglial cells [4] . 28
Inflammation represents a potential means of modifying AD pathogenesis, with the link between 29 peripheral inflammation, TNF-α and neuroinflammation suggesting that TNF-α inhibition may 30 reduce the risk of AD. 31 32 AD was found to be more prevalent in RA patients in a nested case-control study of 8.5 million 33 commercially insured adults. Additionally, it was observed that the risk of AD was lower among 34 RA patients who had been exposed to the TNF-α inhibitor etanercept, suggesting that anti-TNF 35 therapy with etanercept could be a potential treatment for AD [5] . The potential role of 36 etanercept as a treatment for AD has gained further media exposure from a recent Washington 37
Post report that analysis conducted by Pfizer, which holds the patent for etanercept outside of 38 the USA, observed a similar decrease in risk of AD in RA patients exposed to etanercept based 39 on insurance claim data [6] . Pfizer, however, elected not to proceed with a clinical trial which was estimated to cost $80 million, according to critics, because etanercept was reaching the 41 end of its patent life, though Pfizer denies this was a factor [6] . 42
43
While randomized control trials (RCTs) can be reliably used for estimating causal effects, they 44 are expensive to conduct and not all drug targets can be tested in an RCT framework due to 45 ethical considerations or the time-scale involved may be prohibitive. A novel method for 46 estimating the causal effect of drug targets on a disease outcome is Mendelian randomization 47 (MR). MR is a method that estimates the causal effect of an exposure on an outcome by using 48 genetic variants as a proxy for the exposure administered as an intervention in an RCT [7] . MR 49 is analogous to an RCT due to the random allocation of genotypes from parents to offspring at 50 conception (randomization in an RCT) and is thus not affected by reverse causation or 51 confounding variables. In the context of drug development, genetic variants are selected that 52 mimic the action of a drug target, with one allele associated with an altered gene or protein 53 expression (the drug in an RCT) to that of a neutral allele that serves as a reference (the 54 placebo in an RCT) [7] . If the altered genetic allele is associated with a pathway that is 55 causative of the disease, the MR study will detect a change in the clinical outcome. A drug 56 target that has a causative effect on disease is a potential target for drug development, whereas 57 the reverse is true if it is not causative. 58
59
In this study, we use Mendelian randomization to evaluate if RA, TNF gene expression and 60 TNF-α levels are causally related to AD risk. 61
Methods 62

Instrument Selection 63
We obtained cis-eQTL data derived from whole blood for TNF expression from the eQTLGen 64 project (n = 31,684) [8], pQTL data derived from whole blood TNF-α levels (n = 8,293) [9], and genome-wide significant SNPs for RA from a previous GWAS meta-analysis (14,361 RA cases 66 and 43,923 controls) [10] . To obtain independent SNPs, linkage disequilibrium clumping was 67 performed by excluding SNPs that had an r2 > 0.001 with another variant with a smaller p-value 68 association within 1000kb use a reference panel of European individuals from 1000 Genomes 69 Project (phase 3). Three independent eQTLs for TNF, six nominally significant (p < 5e-6) 70 independent TNF-α pQTLs, 56 independent SNPs for RA were selected for analysis. As the 71 effect sizes of the eQTLs were not available in the summary data, the effect sizes were 72 estimated from z-statistics as previously described [11] . 73
74
The GWAS summary data for AD were from the most recent meta-analysis conducted by the 75
International Genomics of Alzheimer's Project comprised of 21,982 cases and 41,944 76 cognitively normal controls (Stage 1 discovery) [12] . The SNPs corresponding to the TNF 77 eQTLs, TNF-α pQTLs, and RA SNPs were extracted from the AD GWAS and were harmonized. 78 79
Mendelian Randomization Analysis 80
We used two-sample MR to estimate the causal effect of TNF expression, TNF-α levels, and RA 81 on AD. For each variant, we calculated an instrumental variable ratio estimate by dividing the 82 SNP-exposure by SNP-outcome and coefficients. An overall estimate of the causal effect was 83 calculated by combining the individual SNP estimates in a fixed-effects meta-analysis using an 84 inverse-variance weighted (IVW) approach [13] . In order to account for potential violations of the 85 assumptions underlying the IVW analysis, we conducted a sensitivity analysis using MR-Egger 86 regression, which allows all variants to be subject to direct effects [13] and the Weighted 87
Median Estimator (WME), which takes the median effect of all available variants, allowing 50% 88 of variants to exhibit horizontal pleiotropy [13] . Heterogeneity was tested using Cochran's Q 89 statistic [13] . 90
The proportion of variance in the exposure explained by each instrument were calculated as 91 previously described [14] . Power calculations were conducted using the mRnd power 92 calculation tool [15] . All statistical analyses were conducted using R version 3.5.2, with 93 Mendelian randomization analysis was performed using the 'TwoSampleMR' package [13] . 94 95
Results
96
The selected instruments for TNF expression, TNF-α levels, and RA risk explained 5.93% (F = 97 285), 1.68% (F = 23.6), and 19.2% (F = 247) of the variance respectively. Given a sample size 98 of 63,926 with the proportion of cases equal to 0.34, this study was adequately powered to 99 detect an OR of any AD of 1.1 for TNF expression, 1.19 for TNF-α levels and 1.055 for RA. 100
101
There was no evidence of a causal association of TNF expression, TNF-α levels or RA on AD 102 risk in the IVW, WME, or MR-Egger regression analyses (Table 2) . Similarly, there was no 103 causal association for the individual TNF eQTLs. There was evidence of heterogeneity (Q = 104 84.8, df = 54, p = 0.00472) in RA analysis, but not for the TNF (Q = 3.46, df = 2, p = 0.177) or 105 TNF-α (Q = 2.78, df = 5, p = 0.733) analysis. 106
107
Discussion 108
This study examined the causal association of blood TNF expression, serum TNF-α levels and 109 RA with AD risk using Mendelian randomization. Despite adequate statistical power to detect an 110 effect, we do not find any evidence that increased TNF expression, TNF-α levels or RA risk are 111 causally associated with increased AD risk. These results suggest that TNF-α antagonists, such 112 as etanercept, are unlikely to reduce the risk of AD. 113 114 Incidence of AD was reported to be lower in RA patients in a meta-analysis of 10 studies, 115 however, an MR analysis conducted using an earlier AD GWAS also found no causal effect of 116 RA on AD [16] . While animal studies of AD models suggest that TNF-α inhibition ameliorates 117 AD-related pathology, only a few human studies have been conducted [17] . An open-label 118 clinical trial conducted in mild-severe AD patients (n = 15) found that perispinal extrathecal 119 administration of etanercept was associated with significant improvement in cognitive function 120 [18] . In contrast, a double-blind study of etanercept conducted in patients with mild-moderate 121 AD (n = 41) over a 24-week period, found that subcutaneous administration of etanercept 122 showed no effect on cognitive, functional or behavioral assessments [19] . 123
124
The results of this study should be interpreted in conjunction with its limitations. First, the 125 analysis conducted here was restricted to the expression of TNF mRNA in whole blood, the 126 tissue in which the largest eQTL studies have been conducted to date. Analysis in additional 127 tissues may implicate TNF expression as a causal risk factor, however, the sample sizes 128 available for other tissues are 30x smaller than that of whole blood and thus have considerably 129 reduced power [20] . Second, the TNF-α GWAS did not contain any genome-wide significant 130 hits, as such, we used nominally significant hits which can result in the inclusion of weak 131 instruments and bias results towards the null. Finally, these MR estimates represent the effect 132 of lifelong exposure to increased TNF expression or TNF-α levels, while drugs generally have 133 shorter periods of exposure, and may not distinguish between critical periods of exposure [7] . 
